5th HIV Research for Prevention Conference (HIVR4P 2024)

Sessions & Speakers

1. Sunday 10/06

   Satellite | 14:30–16:00 PET (GMT-5 hours) | Limatambo 2/Channel 2

   Delivering on the promise: Defining optimal implementation strategies and service delivery packages for the Dual Prevention Pill (Abstract)
   

   AVAC, Population Council, UNICEF

2. Monday 10/07

   Press Conference | 10:00–11:00 PET (GMT-5 hours) | Press Conference Room

   HIVR4P Scientific Highlights press conference

    

   “Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg)”

   Jeremy Nuttall

   (Oral presentation will take place on 9 October)

   E-poster | NA | Online

   “’DPP is good because you will be taking it as one pill’ Attitudes and experiences with the dual prevention pill (DPP) among adolescent girls and young women in Harare, Zimbabwe” (Abstract)

   A. Dandadzi*, I. Bruce, N. Sedze, M. Frix, P. Musara, P. Mutero, C. Murombedzi, B.A. Friedland, N. Mgodi, and S. Mathur

    

   “End user market segmentation, messaging and positioning for the dapivirine vaginal ring: A Lesotho case study” (Abstract)
   

   D. Pillay*, F. Mahiaini, D. Phenethi, S. Pato, S. Tenn, M. Motlatsi, and L. Solai

    

   “High levels of vulnerability among adolescent girls and young women (AGYW) enrolled in a crossover pilot study of a dual prevention pill for HIV and pregnancy prevention in Harare, Zimbabwe” (Abstract)

   M. Nkangu*, M. Plagianos, A. Dandadzi, V. Gatsi, S. Matimbira, C. Murombedzi, P. Musara, I.V. Bruce, J.B. Burnett-Zieman, N.M. Mgodi, S. Mathur, and B.A. Friedland

3. Tuesday 10/08

   Symposium | 13:30–15:00 PET (GMT-5 hours) | Limatambo 5/Channel 3

   Session: Other prevention modalities and cross-cutting issues

    

   “Multipurpose technology in STI control”

   Lisa Haddad*

   Poster Late Breaker | 17:00–19:00 PET (GMT-5 hours) | Poster Exhibition (Levels 3&4)

   “Correlates of adherence to oral PrEP or a dual prevention pill in a crossover clinical trial in Harare, Zimbabwe and Johannesburg, South Africa” (Abstract)

   Marlena Plagianos*, D. Bryant, C. Murombedzi, B. Zieman, S. Mathur, I. Bruce, A. Dandadzi, P. Musara, S. Zulu, K. Reddy, N. Cassim, L. Haddad, T. Palanee-Phillips, N. Ndlovu, N. Mgodi, B. Friedland

4. Wednesday 10/09

   Oral Late Breaker | 10:30–12:00 PET (GMT-5 hours) | Limatambo 3/Channel 1

   “Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg)” (Abstract)
   

   J. Nuttall,* L. Haddad, M. Plagianos, W. Kriel, J. Visser, L. Solai, A. Garg, J. Steytler, and B. Devlin

   Oral | 17:30–19:00 PET (GMT-5 hours) | Limatambo 3/Channel 1

   “Are women interested in a nonhormonal multipurpose prevention technology (MPT) vaginal ring? Results from a national online survey with U.S. women” (Abstract)

   Ann Gottert, S. Mathur*, T. Abuya, I. Bruce, S. Shetty, M. Nguyen, J.M. Sales, L.B. Haddad, and B.A. Friedland

   Poster Exhibition | 19:00–20:30 PET (GMT-5 hours) | Poster Exhibition (Levels 3&4)

   “Acceptability of the 3-month dapivirine ring versus the 1-month dapivirine vaginal ring: Qualitative findings from a crossover bioavailability trial among 18- to 45-year-old women in Bloemfontein, South Africa” (Abstract)

   B. Friedland, M Nunu, S Clarke-Von Witt, E Dorman, J Visser, W Kriel, J Steytler, and B Devlin

    

   “Comparison of self-reported, pill count and biomarker measures of adherence to oral PrEP or a dual prevention pill in crossover clinical trial in Harare, Zimbabwe” (Abstract)

   Marlena Plagianos*, N.M. Mgodi, B. Zieman, S. Mathur, I. Bruce, A. Dandadzi, P. Musara, C. Murombedzi, L. Haddad, and B. Friedland

    

   “Development of a multipurpose intravaginal ring for controlled release of Q-Griffithsin combined with contraceptive hormones: In vitro and in vivo evaluation” (Abstract)

   M.M. Baum, M. Gunawardana, J. Breslin, I. Butkyavichene, A.E. Castonguay, D.B. Diener, S. Gunawardana, M. Remedios-Chan, J.A. Moss, P. Barnable, T. Bonnaire, J. Fernandez-Romero, M. Aravantinou, F. Schiro, B. Grasperge, N. Derby, P. Angsantikul, N. Kumar, B. Variano, and Natalia Teleshova*

    

   “Experiences with and recommendations for a dual prevention pill (DPP) for HIV and pregnancy prevention: in-depth interviews with women participating in a crossover acceptability study in Johannesburg, South Africa

   S. Tenza^*, M. Moji, P. Sibiya, P. Makau, S.K. Zulu, I. Bruce, K. Reddy, B. Friedland, T. Palanee-Phillips, and S. Mathur

    

   “Preference for and adherence to a dual prevention pill (DPP) versus two separate pills for PrEP and contraception among women in Johannesburg, South Africa” (Abstract)

   B. Zieman, Marlena Plagianos*, T. Palanee, S. Reddy, N. Ndlovu, S. Zulu, I. Bruce, S. Mathur, L. Shale, L.B. Haddad, and B. Friedland

    

   “Safety/pharmacokinetics/pharmacodynamics and immunogenicity studies of Griffithsin fast dissolving insert in rhesus macaques” (Abstract)

   P. Barnable, M.L. Visciano, M. Aravantinou, N. Kommineni, J. Gadsden, F. Schiro, L. Guzmán, B. Grasperge, P. Angsantikul, J. Fernandez-Romero, L.B. Haddad, and Natalia Teleshova*